Plasma-Derived Therapy for Hemophilia in The Updated European Medicines Agency’s Union List
Deborah Hibbett, Senior Vice President, Head of Global Corporate Affairs and Sustainability, Plasma-Derived Therapies at Takeda, shared on LinkedIn:
”The updated European Medicines Agency’s Union List of Critical Medicines now includes a plasma-derived therapy for hemophilia patients with inhibitors.
This addition underscores that reliable, uninterrupted access to critical medicines – including this product and the other listed plasma-derived therapies – is essential for patients, families and healthcare systems.
Takeda celebrates this update as we are also committed to the bleeding disorders community and to creating value through sustainable, equitable access – including our renewed collaboration with the WFH Humanitarian Aid Program and the work highlighted in Takeda’s 2025 Access to Medicines Update.
Thank you to the healthcare community, patient advocates and partners who continue to advance security of supply and equity in care every day.”
Stay updated with Hemostasis Today.
-
May 27, 2026, 04:47Daniel Torrent: The Overlooked Epidemic of Post-Thrombotic Syndrome
-
May 27, 2026, 04:45Graziella Pompei: Is Aspirin Still a Valid Alternative to Clopidogrel in PCI with DES Implantation?
-
May 27, 2026, 04:40Kausik Ray: Phase 1 Trial Highlights Anti-Inflammatory Effects of Ruvonoflast
-
May 27, 2026, 04:29Francisco Chacón-Lozsán: High-Sensitivity Troponin and the Evolving Management of NSTEMI
-
May 27, 2026, 04:14Michael R. Jaff: HI-PEITHO Trial and NEWS Score Insights on Advances for Intermediate-Risk Pulmonary Embolism
-
May 26, 2026, 16:45Ashley George: Take the Leap for Thrombosis UK
-
May 26, 2026, 16:40Hamed Helisaz: Machine Learning for Detecting Missing Heart Medications
-
May 26, 2026, 15:32Haroun Gajraj: Brown Marks After Microsclerotherapy – What Every Practitioner Needs to Know
-
May 26, 2026, 15:29Jacqueline van Paassen: Lack of Essential Clinical Data in DOAC Prescriptions in Community Pharmacies